- Lp(a), lipoprotein(a), pronounced “L-P-little-a”, is an inherited lipid particle that raises the risk of heart attack, stroke, and aortic valve disease, independently of LDL cholesterol.
- Levels are almost entirely determined by genetics. Diet, exercise, and most standard cholesterol medications make very little difference.
- Around one in five people has an elevated Lp(a), yet most have never had it measured.
- It is one of the most common explanations for a high calcium score in someone with an otherwise reasonable lipid profile.
- New RNA-based therapies in late-stage trials are showing dramatic reductions in Lp(a) levels, this is one of the most exciting areas in preventive cardiology right now.
- Elevated Lp(a) is not a reason for despair, it is information. It means managing every other risk factor as well as possible, and staying close to the emerging treatment landscape.
One of the most common scenarios I encounter in my clinic is a patient who comes in with a high coronary calcium score, a test that measures plaque buildup in the arteries, but whose cholesterol looks perfectly reasonable. Their LDL is fine. Their HDL is decent. They exercise, they eat well. And yet their calcium score tells a different story.
More often than not, when I check their Lp(a), the answer is sitting right there.
Lipoprotein(a) is a lipid particle that most people have never heard of and most doctors haven’t routinely measured, until recently. That is changing fast. Understanding what it is, whether you should be tested, and what elevated levels mean is increasingly important for anyone serious about their cardiovascular health.
What Is Lp(a)?
The basics
Cholesterol can’t travel freely in the bloodstream, it’s a fat, and fats aren’t water-soluble. The body packages cholesterol inside protein-coated transport particles called lipoproteins. LDL and HDL are the most familiar. Lp(a) is structurally similar to LDL, but with an extra protein, called apolipoprotein(a), attached to it.
That extra protein is what makes Lp(a) uniquely problematic. It is structurally similar to plasminogen, a protein involved in dissolving blood clots. This appears to be why high Lp(a) both promotes atherosclerosis and interferes with the body’s natural clot-dissolving system, making arterial plaques more dangerous.
Why it’s different from LDL
LDL can be meaningfully reduced by diet, exercise, and statins. Lp(a) cannot. Levels are almost entirely determined by genetics, fixed from birth, stable throughout adult life, and largely unresponsive to lifestyle changes or most standard medications.
This is what makes it both important and frustrating: it is a significant risk factor you cannot simply lifestyle your way out of.
Why Does It Matter?
Independent cardiovascular risk
Elevated Lp(a) independently raises the risk of coronary artery disease, heart attack, stroke, and calcific aortic valve stenosis. The word “independently” is critical here, it operates on top of, and separately from, your LDL level.
You can have a well-controlled LDL and still carry significantly elevated cardiovascular risk if your Lp(a) is high. Standard cholesterol management will not address it.
The calcium score puzzle
Lp(a) is one of the most common explanations for what I call the calcium score paradox, a high calcium score in someone whose conventional lipid profile looks fine. If that scenario sounds familiar, an Lp(a) test is one of the most informative next steps available.
It is also frequently the hidden explanation behind premature heart disease, heart attacks in younger people, or cardiovascular events in those whose known risk factors appear well managed.
I always say to patients: if you’ve had a cardiovascular event that doesn’t make sense given your risk factors, or your calcium score is higher than expected, Lp(a) is one of the first things I want to check. It fills in gaps that nothing else explains.
Who Should Be Tested?
Current guidelines recommend Lp(a) be measured at least once in every adult’s lifetime. In practice, it is particularly important for:
Family history
Heart attack or stroke before 55 in a male relative, or before 65 in a female relative.
High calcium score
Elevated calcium score despite a reasonable lipid profile, Lp(a) is frequently the missing piece.
Premature heart disease
A cardiovascular event that doesn’t fit the expected risk profile, younger age, well-managed risk factors.
Familial hypercholesterolaemia
Inherited high cholesterol, Lp(a) testing adds important additional risk information.
Aortic valve disease
Elevated Lp(a) is associated with calcific aortic stenosis, testing is recommended as part of assessment.
General screening
Guidelines recommend at least one Lp(a) measurement in every adult’s lifetime, it only needs to be done once.
The test itself is a simple blood test. Levels above approximately 50 mg/dL (or 125 nmol/L) are generally considered elevated, though risk increases continuously rather than having a sharp cut-off point.
What Can Be Done About It?
The honest answer about lifestyle
Unlike LDL, Lp(a) does not respond meaningfully to diet, exercise, or weight loss. This is frustrating to hear, but it is important to understand, because it means lifestyle changes alone will not solve the problem. They still matter enormously for overall cardiovascular risk, just not for Lp(a) specifically. A Mediterranean-style diet, regular exercise, and not smoking all reduce overall cardiovascular risk, they just don’t lower Lp(a) itself.
Current medications
There is currently no approved medication that specifically and substantially lowers Lp(a). Statins, the cornerstone of cholesterol management, have a neutral to slightly raising effect on Lp(a), though their overall cardiovascular benefit still far outweighs this. PCSK9 inhibitors such as evolocumab and alirocumab produce a modest Lp(a) reduction of around 20–30% as a secondary effect alongside their primary LDL-lowering action, which may be clinically useful in some patients.
The emerging treatments, genuinely exciting
This is where the story gets very interesting. Two RNA-targeted therapies, pelacarsen and olpasiran, are specifically designed to reduce Lp(a) production in the liver, and the results from clinical trials have been dramatic. Reductions of 70 to over 95% in Lp(a) levels have been achieved. This mirrors the approach being explored for RNA-based therapies in blood pressure treatment, a broader shift in how cardiovascular medicine is approaching genetic risk factors.
Both agents are currently in large Phase 3 cardiovascular outcomes trials, designed to determine whether those dramatic Lp(a) reductions translate into fewer heart attacks and strokes. At the ACC 2026 meeting in New Orleans, emerging data from these trials generated significant interest, with early signals that are encouraging. Results are anticipated within the next few years.
If the outcomes data confirms what the mechanistic and biomarker data suggest, this will represent a genuinely transformative development for the one in five people carrying elevated Lp(a), a group that has until now had no specific pharmacological option.
| Intervention | Effect on Lp(a) | Effect on overall CV risk |
|---|---|---|
| Diet and exercise | Minimal | Meaningful, reduces LDL, BP, inflammation |
| Statins | Neutral to slight increase | Major, dramatically reduces LDL and events |
| PCSK9 inhibitors | Modest reduction (~20–30%) | Major, may add Lp(a) benefit alongside LDL lowering |
| Pelacarsen / olpasiran | Very large reduction (70–95%+) | Outcomes trial results anticipated, signals encouraging |
| Smoking cessation | Minimal direct effect | Very significant, one of the most impactful changes possible |
What to do right now
While the specific Lp(a)-lowering treatments mature, the management strategy is clear: treat elevated Lp(a) as a signal to optimise everything else. Blood pressure at target. LDL as low as possible. Not smoking. Weight and activity levels healthy. Appropriate cardiac surveillance in place, including, where relevant, a CT coronary angiogram to directly assess the state of the coronary arteries.
Elevated Lp(a) does not mean a cardiovascular event is inevitable. It means the margin for error on other risk factors is smaller, and that managing them well matters more, not less. The role of inflammation markers such as hs-CRP alongside Lp(a) is also worth understanding, these two markers reflect distinct risk pathways and neither tells the full story on its own.
Free Download, Heart Matters
Our Heart Health Risk Factor Checklist covers 12 cardiovascular risk categories, including Lp(a), with a traffic light self-assessment and space for questions to raise with your doctor. Free to download and bring to your next appointment.
Heart Matters Resource
When in Doubt, Get Checked Out
If you have a family history of early heart disease, a high calcium score, or a cardiovascular event that doesn’t fit your known risk factors, asking your doctor about an Lp(a) test is one of the most worthwhile conversations you can have.
Conclusion
Lp(a) is a risk factor that affects one in five people, is almost entirely genetic, and until very recently had no specific treatment. That is why it has been underappreciated, and why the emerging RNA therapies represent such a significant moment for preventive cardiology.
If you have had a high calcium score with a reasonable lipid profile, a cardiovascular event that didn’t quite make sense, or a strong family history of heart disease, an Lp(a) test is a simple, once-in-a-lifetime blood test that could genuinely change the conversation with your doctor.
The treatment landscape is moving quickly. If your Lp(a) is elevated, staying engaged with your cardiologist and the emerging evidence puts you in the best possible position as the new therapies arrive.
More from Heart Matters
- What Is Atherosclerosis?
- The hs-CRP Test, Inflammation, Heart Risk, and Why Context Matters
- Beyond Statins: PCSK9 Inhibitors and the Future of Cholesterol Management
- Coronary Artery Disease, Heart Matters Dedicated Resource
- The Coronary Calcium Score: What It Measures and What to Expect
- Free Resources, Heart Health Risk Factor Checklist
